Open AccessNovel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物：第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物)
Author(s) -
Grunberger George
Publication year - 2013
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.12046
Subject(s) - incretin , medicine , type 2 diabetes mellitus , diabetes mellitus , glucagon like peptide 1 , exenatide , dipeptidyl peptidase 4 , saxagliptin , sitagliptin , type 2 diabetes , intensive care medicine , pharmacology , endocrinology
The present short review summarizes and updates clinical experience with two classes of drugs introduced for the management of type 2 diabetes mellitus over the past 8 years: (i) the glucagon‐like peptide‐1 receptor agonists; and (ii) the dipeptidyl peptidase 4 inhibitors. Both classes of agents address the so called “incretin defect” in patients with T2DM .